DBV Technologies Plunges By Half On Allergy Drug Trial's Failure

Shares of DBV Technologies (DBVT) lost roughly half their value after Friday's close on reports that the company's test of a drug to treat peanut allergies failed a key technical study, while rival Aimmune Therapeutics (AIMT) soared on the news.

XAutoplay: On | OffThe stock of drug developer DBV plummeted by more than 50% in after-hours trading on the news, and were down 48% to 25 in late action — a loss of 23.07. Aimmune, meanwhile, soared by more than 46% to 37.50 late Friday afternoon.

What feeling does this article give you?

#hashtags to follow:

Shares of DBV Technologies [+]    DBVT [+]    Aimmune Therapeutics [+]    AIMT [+]    XAutoplay [+]    DBV [+]    Aimmune [+]   

More #news: